Looking for the latest Government Contracting News? Check out our story: Draper Develops CBRN Hazard Sensor for Small UAVs. Click to read the full story!
Handling, Zuführung und Beladung von Produkten: Robotik Pick-and-Place Plattform Syntegon RPP
Kernaufgaben der neu entwickelten Robotik Pick-and-Place Plattform Syntegon RPP von Syntegon Technology sind Qualitätssicherung, Bedienfreundlichkeit sowie effiziente Produktionsprozesse. Mit der Plattform lassen sich Prozessschritte wie Handling, Zuführung und Beladung automatisieren. Die Robotik-Plattform ist wie ein Baukasten konzipiert. Das ermöglicht die individuelle Konfiguration der Roboterzellen. Die Delta-Roboter lassen sich flexibel zusammenschalten und in Verbindung mit Transportmodulen .
Den vollständigen Artikel lesen .
FNRD-2.622.0
Wie bewerten Sie die aktuell angezeigte Seite?sehr gut123456schlechtProblem melden
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen.
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2021. The Company reported first quarter net sales of $1.847 billion, an increase of 3.6% over the prior year period, and an increase of 0.8% on a constant currency basis. Net earnings for the first quarter were $198.1 million, or $359.1 million on an adjusted basis.
Message :
Required fields
WARSAW, Ind., May 4, 2021 /PRNewswire/ Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2021. The Company reported first quarter net sales of $1.847 billion, an increase of 3.6% over the prior year period, and an increase of 0.8% on a constant currency basis. Net earnings for the first quarter were $198.1 million, or $359.1 million on an adjusted basis.
Diluted earnings per share were $0.94 for the first quarter. Adjusted diluted earnings per share were $1.71 for the first quarter, an increase of 0.6% over the prior year period. Our performance was stronger than we anticipated in the first quarter, as we saw signs of the pandemic beginning to subside across many regions toward the end of the quarter driven by acceleration of vaccine rollout. As we move into the second quarter, we expect that momentum to continue and believe we are well-positioned to meet the needs of our